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Highlights 
 Prognostic impact of monosomal karyotype appears dependent on karyotype complexity 
 Monosomy 5 lacks prognostic impact in context of AML with monosomal karyotype 
 Monosomy 17 independently predicts for inferior survival among AML patients 
 
Abstract   
The presence of a monosomal karyotype (MK+) and/or a complex karyotype (CK+) identifies subcategories of 
AML with poor prognosis. The prognostic significance of the most common monosomies (monosomy 5, 
monosomy 7, and monosomy 17) within MK+/CK+ AML is not well defined.  We analyzed data from 1,592 AML 
patients age 17-93 years enrolled on ECOG-ACRIN therapeutic trials.  The majority of MK+ patients (182/195; 
93%) were MK+/CK+ with 87% (158/182) having ≥5 clonal abnormalities (CK≥5).  MK+ patients with karyotype 
complexity ≤4 had a median overall survival (OS) of 0.4y compared to 1.0y for MK- with complexity ≤4 
(p<0.001), whereas no OS difference was seen in MK+ vs. MK- patients with CK≥5 (p=0.82). Monosomy 5 
(93%; 50/54) typically occurred within a highly complex karyotype and had no impact on OS (0.4y; p=0.95).  
Monosomy 7 demonstrated no impact on OS in patients with CK≥5 (p=0.39) or CK≤4 (p=0.44).  Monosomy 17 
appeared in 43% (68/158) of CK≥5 patients and demonstrated statistically significant worse OS (0.4y) 
compared to CK≥5 patients without monosomy 17 (0.5y; p=0.012).  Our data suggest that the prognostic 
impact of MK+ is limited to those with less complex karyotypes and that monosomy 17 may independently 
predict for worse survival in patients with AML.    
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Introduction 
Despite the increasing use of molecular characterization of mutations in the prognostic risk classification of 
acute myeloid leukemia (AML), conventional cytogenetic studies at diagnosis remain a highly influential risk 
factor.  The presence of a complex karyotype (CK+)1,2 or monosomy of either chromosome 53  or chromosome 
74 has been universally associated with unfavorable prognosis.  Recently the UK MRC added monosomy 17 to 
its list of independent predictors of poor outcome with their refinement of the AML cytogenetic classification 
categories.5  Although there has been no change in induction therapy for nearly 4 decades6, subgroups that 
respond particularly well or poorly have been identified based on their genetic features.1,4,5,7-9 Careful 
examination of disease characteristics at diagnosis is imperative to identify high-risk patients and to 
appropriately apply risk-adapted molecularly targeted therapies or intensified treatment strategies including 
hematopoietic stem cell transplantation (HSCT). 
 The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer 
Research (HOVON/SAKK) group was the first to demonstrate the potential of monosomal karyotypes (MK) to 
delineate a subgroup with very poor risk and thus refined the cytogenetic classification of AML patients < 60 
years.8   MK+ was defined as either the presence of two or more autosomal monosomies or one monosomy 
plus at least one structural abnormality and was associated with a 4% 4-year overall survival (OS) compared to 
26% for MK- patients.  Particularly unfavorable outcomes in MK+ patients > 60 years were reported by the 
Southwest Oncology Group (SWOG) with a 4-year OS of 1% and less than one third of MK+ patients between 
ages 31 to 60 years achieved complete remission (CR).10   
Haferlach and colleagues in the Munich Leukemia Laboratory Group reported that complex karyotype 
defined as ≥4 unrelated abnormalities identified the largest proportion of very poor risk AML patients and 
suggested that the combination of CK≥4 and MK+ status would be the most sensitive metric in identifying 
those with unfavorable prognosis.11  Additionally, degree of cytogenetic complexity has been shown to identify 
the subgroups of MDS patients with the worst prognosis, independent of MK+ status.12,13  In fact, when 
accounting for karyotype complexity MK was not an independent prognostic factor in patients with 
myelodysplastic syndrome.12,13   
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 Whether the prognostic value of specific monosomies such as monosomy 5, monosomy 7, or 
monosomy 17 is preserved in the context of MK+ AML is uncertain.  Therefore, we conducted a retrospective 
analysis of AML patients enrolled in four Eastern Cooperative Oncology Group and the American College of 
Radiology Imaging Network Cancer Research Group (ECOG-ACRIN) therapeutic clinical trials between 1990 
and 2008 to determine whether individual monosomies, karyotype complexity, age, or baseline disease 
characteristics impact outcome in MK+ disease.   
Methods  
Patients 
Eligible patients for this study were defined as previously untreated AML patients enrolled in one of four 
prospective ECOG-ACRIN therapeutic clinical trials (E1490, E1900, E3993, and E3999) between 1990 and 
2008. 14-17 
Newly diagnosed AML patients (excluding acute promyelocytic leukemia) were eligible for enrollment 
onto the therapeutic protocols.  Except for those enrolled onto E1900, patients were required to be at least 55 
years of age.  All patients received induction chemotherapy containing cytarabine combined with daunorubicin, 
idarubicin, or mitoxantrone +/- additional investigational agents as defined by the respective protocol.  Post-
remission therapeutic strategies were defined per individual protocol and not influenced by the identification of 
MK+ disease.  All patients signed informed consent prior to enrollment.  The studies were approved by ethics 
committees of all participating institutions and conducted in accordance with the Declaration of Helsinki.  A 
total of 1,592 AML patients ranging 17-93 years of age were enrolled on the aforementioned trials.    
Evaluable cytogenetics data are available on 1,188 patients included in this analysis. Patients enrolled 
on E1900 accounted for the largest number of the 1,188 patients (45%; 535), followed by those on E3999 
(29%; 345), E3993 (22%; 266), and E1490 (4%; 42).      
Cytogenetic evaluation 
Diagnostic bone marrow aspirate or heparinized peripheral blood was examined for cytogenetic abnormalities 
by unstimulated standard culturing and banding techniques by individual institutional or referral cytogenetic 
laboratories.  Results and karyotypes were centrally reviewed by the ECOG-ACRIN Cytogenetics Committee 
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and designated in accordance with the International System for Human Cytogenetic Nomenclature (ISCN).   
Karyotypic analysis was based on minimum review of 10 available metaphases.  Normal karyotype required a 
minimum of 20 normal diploid metaphases.  Abnormalities were considered clonal when at least 2 metaphases 
had the same structural abnormality or the same trisomy or when at least 3 metaphases displayed the same 
monosomy.  Structural abnormalities were defined as deletions, translocations, inversions, and additions for 
the purposes of this study and in accordance with the definition used by HOVON/SAKK8  The following clonal 
abnormalities were scored for each chromosome: monosomies, extra copies, structural abnormalities, ring 
chromosomes as well as the frequency of the individual abnormalities.  Marker chromosomes and double 
minutes were also documented. Complex karyotype was defined as ≥ 3 clonal abnormalities in accordance 
with the National Comprehensive Cancer Network18 and the European Leukemia Net recommendations19.  
Degree of cytogenetic complexity was also recorded for CK+ patients having 3, 4, or ≥5 clonal abnormalities.  
Patients with core-binding factor (CBF) leukemia [t(8;21), inv(16) or t(16;16)] were excluded from the MK+ 
cohorts regardless of the presence of additional clonal abnormalities. 
Statistical Analysis 
Patient baseline characteristics were compared using Fisher’s exact test if they were categorical and Wilcoxon 
rank sum tests if they were continuous. OS was defined as time from study randomization/registration to death 
from any cause, with follow-up censored at the date of last contact. Kaplan-Meier estimates were used to 
estimate the event-time distributions for OS.  Log-rank tests stratified on studies and induction treatments were 
used to examine the effects of MK or other chromosomal abnormalities on OS. Multivariate Cox model 
stratified on studies and induction treatments was performed on OS to examine the prognostic effect of MK or 
other chromosomal abnormalities while controlling for potential risk factors {Multivariate analysis included the 
factors of MK+ status, karyotype complexity, gender, age, WBC count, hemoglobin, platelet count, marrow and 
blood blast %, secondary vs de novo AML, and the occurrence of independent high-risk cytogenetic 
abnormalities [del5q, del7q, del17p, inv3, t(6;9), 11q23, and t(9;22)] where appropriate}. All P values were 
based on 2-sided tests. 
Results 
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Cytogenetic Abnormalities 
Cytogenetics were evaluable in 1188 / 1592 (75%) of AML patients enrolled onto the four protocols.  An 
overview of the frequency of normal as well as clonal cytogenetic abnormalities is seen in Table 1.  Normal 
karyotype AML occurred in 502 (42%) patients whereas 686 (58%) had clonal cytogenetic abnormalities.  CBF 
leukemia was identified in 108 (9%) patients.  Single monosomies were found in 97 (8%) and multiple 
monosomies in 132 (11%), while 959 (81%) of evaluable patients had no monosomies.  Concurrent structural 
abnormalities were present in 64/97 (66%) of those with a single monosomy with one patient also possessing a 
CBF abnormality [t(8;21)].  CK was present in 251 (23%) and MK was identified in 195 (18%) of non-CBF 
patients.  Multiple monosomies were identified in the majority of MK+ patients (132/195; 68%) compared to 
those with a single monosomy and a structural abnormality (63/195; 32%). All patients with multiple 
monosomies had CK and only 6/132 (5%) patients with multiple monosomies lacked concurrent structural 
abnormalities.   
Baseline Characteristics 
Significant differences were observed in age, WBC count, hemoglobin, platelet count, peripheral and bone 
marrow blast percentages at diagnosis and percentages of secondary AML between MK+ and MK- patients 
(Table 2). MK+ patients tended to be older and have a lower presenting WBC count, lower percentage of 
circulating or bone marrow blasts, lower hemoglobin, and a lower platelet count at presentation.  MK occurred 
in 7% (25 / 383) patients <55 years compared to 21% (170 / 805) patients ≥55 years (p<0.001).   
Monosomies were detected for each chromosome at least once, but occurred least frequently with 
chromosomes 1, 2, 8, and 15.  Monosomy 7 accounted for 53% (51/97) of the single monosomies and was 
present in 47% (107/229) of all patients in whom monosomies were identified.  Monosomy 17 was the most 
frequent monosomy occurring in patients containing multiple monosomies (48%; 64/132), followed by 
monosomy 7 (42%; 56/132) and monosomy 5 (39%; 52/132) (Table 3). Double monosomies of individual 
chromosomes were uncommon (12%; 16/132) and affected chromosomes 3, 5, 9, 12, 13, 14, 15, 16, 17, 18, 
20, and 21.   
Prognostic Associations  
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Median follow-up of the patients included in this analysis was 5.2 years. CR rate amongst all 1,188 evaluable 
patients was 53.4%.  Outcome measures based on MK+/- status of the 578 patients with non-CBF clonal 
abnormalities are reported in Table 4.   CR was achieved in 31% (61/195) of MK+ non-CBF patients compared 
to 47% (179/383) of MK- non-CBF patients with a 4-year OS of 3% and 14% (P<0.001), respectively.  Among 
patients ≥ 55 years, CR occurred in 30% (51/170) of MK+ non-CBF patients compared to 42% (116/276) of 
MK- non-CBF patients and was associated with a 4-year OS of 1% versus 10%, respectively (p<0.001).  MK+ 
non-CBF patients <55 years achieved CR at a rate of 40% (10/25) compared to 59% (63/107) in MK- non-CBF 
patients and was related to a 4-year OS of 16% versus 27%, respectively (p=0.02).     
CR was achieved in 22% (14/63) of patients with a single monosomy and structural abnormalities 
compared to 33% (11/33) with an isolated monosomy (p=0.33, with 4-year OS of 5% and 9%, respectively 
(p=0.03).   
 
Monosomal Karyotype 
MK+ patients demonstrated an inferior median OS of 0.4 years compared to 1.2 years of the collective 
group of MK- patients (p<0.001).  Evaluation of the impact of the combination of CK+/- and MK+/- status 
among patients with non-core-binding factor (non-CBF) abnormalities demonstrated that the CK-/MK- AML 
patients (n=314) had the best median OS (1.0 years).  MK+ patients fared poorly regardless of the presence or 
absence of CK+ disease with a median OS of only 0.4 years and 0.2 years, respectively (Supplemental Figure 
1).   When accounting for karyotype complexity among patients with at least one clonal abnormality, 22% MK+ 
patients with karyotype complexity ≤4 clonal abnormalities achieved CR compared to 47% of those non-CBF 
MK- AML and the same degree of complexity (p=0.003) (Table 5).  Median OS for MK+ patients with ≤4 clonal 
abnormalities was 0.3 years compared to 1.0 years for those that were MK- with non-CBF clonal abnormalities 
(p<0.001;  HR: 1.98; 95%CI 1.40, 2.81) (Figure 1A).  Of note, median OS was essentially unchanged when 
limiting the analysis to those MK+ patients with karyotype complexities of only 3 or 4 abnormalities (OS 0.3 
years) compared their MK- counterparts (1.1 years; p=0.039;)(Supplemental Figure 2).  MK+ status in patients 
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with karyotype complexity ≤4 remained significant (p=0.01, HR 1.78; 95%CI 1.13, 2.79) by multivariate (Table 
6).  
No difference was seen in CR (38% vs 34%; p=0.82; Table 5) or OS (median 0.5y vs 0.4y; p=0.82;) in 
patients with karyotype complexity ≥5 (CK≥5) and differing MK+/- status (Figure 1B).  MK+ status also failed to 
demonstrate significance within the CK≥5 population (p=0.47) by multivariate (Table 6). 
Monosomy 5 
Monosomy 5 was present in 27% (53/195) of all patients with MK+ and its presence failed to have 
prognostic impact when compared to MK+ patients without monosomy 5 (log rank test p=0.65).  The majority 
of the occurrences of monosomy 5 (98%, 53/54) carried the MK+ designation with 94% (50/53) of monosomy 5 
also having CK≥5.  Survival of MK+/CK≥5 was not impacted by monosomy 5 status (median OS: 0.4y vs. 0.4y; 
Figure 2B).  Monosomy 5 status also failed to demonstrate significance within the MK+/CK≥5 population 
(p=0.94;) by multivariate analysis (Supplemental Table 1). 
Monosomy 5 rarely occurred in patients with non-CBF clonal abnormalities with a karyotype complexity 
≤4 (8%; 3/37), but its presence in this population appeared to be associated with a poor overall survival and a  
HR of 4.13 (95%CI 0.82, 20.8) (Figure 2A) although the small number of occurrences (n=3) in this context 
precludes any definitive statement of significance.    
Monosomy 7 
 Monosomy 7 (+/- monosomy 5 +/- monosomy 17) was identified in 107 patients and the majority (74%; 
79/107) met the criteria for MK+ disease with 63% (59/79) also possessing CK≥5.  CR rates were not different 
for monosomy 7 patients with or without MK+ (32% v. 33%) and were similar (30%) for MK+ patients lacking 
monosomy 7 (MK+/monosomy 7-).  Monosomy 7 status demonstrated no impact on OS of MK+ patients 
(p=0.20). Univariate analysis of MK+ patients with monosomy 7 and karyotype complexity ≤4 revealed median 
OS of 0.3 years compared to 0.2 years for those without monosomy 7 (p=0.44; HR 0.76; 95%CI 0.37, 1,53) 
(Figure 2C).  Similarly, MK+ patients with monosomy 7 and CK≥5 had an OS of 0.5 years versus 0.4 years for 
those without this monosomy (p=0.39; HR 0.86; 95%CI 0.61, 1.21) (Figure 2D).  Interestingly, multivariate 
analysis suggested improved survival among MK+ patients with monosomy 7 compared to those without 
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monosomy 7 in both the CK≤4 (p=0.0005; HR: 0.03; 95%CI 0.004, 0.21) and CK≥5 cohorts (p=0.03; HR 0.62; 
95%CI 0.40, 0.94) (Supplemental Table 2).   
Monosomy 17 
Loss of chromosome 17 occurred with the highest frequency (48%; 64/132) of monosomies detected in 
MK+ patients with multiple monosomies and only 39% (25/64) achieved CR in this context.  All cases of 
monosomy 17 were observed within the context of MK+ disease and none survived beyond 4 years.  The 
presence of monosomy 17 was associated with a median OS of 0.3y compared to 0.5y for MK+ patients 
without monosomy 17 (p=0.004; Supplemental Figure 3.).  Accounting for karyotype complexity, MK+ patients 
with monosomy 17 and complexity ≤4 demonstrated an OS of 0.1 years versus 0.4 years for those without 
monosomy 17 (p=0.06; HR:3.11; 95%CI 0.90, 10.7) (Figure 2E).  Similarly, the HR for this group 
(Monosomy17+/ MK+/ CK ≤4) was 12.67 (95%CI 1.30, 123.30) when multivariate analysis was performed, 
although the small number of occurrences (n=4) again precludes any definitive statements regarding 
significance.  The majority of the occurrences of monosomy 17 (94%, 68/72) were among patients with a highly 
complex karyotype (CK≥5).  The presence of monosomy 17 in this context had an OS of 0.4 years compared 
to 0.5 years in those without this monosomy (p=0.01; HR: 1.53; 95%CI 1.09, 2.13) (Figure 2F).  Similarly, the 
HR for this group (Monosomy17+/ MK+/ CK≥5) was 1.54 (95%CI 1.02, 2.33, p=0.04) when multivariate 
analysis was performed among MK+ patients (Supplemental Table 3).     
Contribution of Concurrent Monosomy 5, 7, and/or 17     
Outcomes of patients with monosomy 5 and/or monosomy 7 and/or monosomy 17 relative to MK+ 
status are presented in Table 4.  In the absence of monosomy 7 and monosomy 17, monosomy 5 occurred in 
13 patients with non-CBF cytogenetic abnormalities with 12/13 being MK+ (CR 25%, 4yOS= 0%).   In the 
absence of monosomy 5 and monosomy 17, monosomy 7 occurred in 74 patients with 28/74 being MK- (CR 
32.1%, 4yOS=11%) and 46/74 being MK+ (CR 30.4%, 4yOS 7%; log-rank test for OS p=0.10).  In the absence 
of monosomy 5 and monosomy 7, monosomy 17 occurred in 33 patients with all being MK+ (CR 36.4%, 4yOS 
= 0%).   Of 172 patients possessing karyotypes with monosomy 5 and/or monosomy 7 and/or monosomy 17, 
only 4% (7/172) were known to be alive at 4 years and each were observed to possess monosomy 7.   
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Karyotypes lacking monosomy 5, monosomy 7, and monosomy 17 occurred in 406/686 (59%) of patients with 
non-CBF clonal abnormalities with 87% (354/406) having MK- and 13% (52/406) having MK+ AML.  Those 
patients with MK- disease lacking monosomy 5 /monosomy 7 /monosomy 17 had a CR of 47.7% and a 4yOS 
of 14% compared to a CR of 26.9% and a 4yOS of 4% for those with MK+ disease also lacking monosomy 5 
/monosomy 7/ monosomy 17 (log-rank test for OS p <0.001).  
In a multivariate model including Monosomy 5 status, Monosomy 7 status, Monosomy 17 status, and 
other risk factors, those with monosomy 7 still showed improved OS compared to those without monosomy 7 in  
MK+/ CK ≤4 patients (p=0.0012; HR: 0.02; 95%CI 0.001, 0.19). In MK+/ CK≥5 patients, monosomy 7 and 
monosomy 17 are still independent prognostic factors. Patients with monosomy 7 (p=0.003; HR: 0.62; 95%CI 
0.40, 0.95) or patients without monosomy 17 (p=0.03; HR: 1.63; 95%CI 1.05, 2.56) had improved OS 
(Supplemental Table 4).  
Discussion 
Through the collective analysis of the data and outcomes of 1,592 patients enrolled onto four prospective 
ECOG-ACRIN AML therapeutic trials, we now contribute a number of new observations relevant to the 
cytogenetic categories of MK+ and CK+ AML.   Monosomy 5 appeared to have no independent prognostic 
value and the negative prognostic value of monosomy 7 was lost in the context of MK+ AML.  Additionally, the 
prognostic value of the MK+ designation appeared to be restricted to those patients with karyotype complexity 
≤4 clonal abnormalities.  However, monosomy 17 was found to occur exclusively within monosomal karyotype 
patients and to independently predict for worse survival among MK+ patients as well as those with highly 
complex karyotypes (MK+/CK≥5).   
Poor prognosis associated with chromosomal aberrations involving the long arm of chromosomes 5 or 
7 [add/del (5q) or add/del (7q)] as well as complete loss of chromosome 5 or 7 (monosomy 5 or monosomy 7) 
has been previously described.1,5  Our data demonstrate that monosomy 5 occurred almost exclusively in the 
setting of MK+ (53/54) and highly complex (50/54 with CK≥5) karyotypes, and that monosomy 5 contributed no 
prognostic value within the CK≥5 patients. This data suggests that the negative impact previously attributed to 
monosomy 5 is actually attributable to karyotype complexity.  Review of the HOVON/SAKK, SWOG, and 
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Groupe Ouest-Est d’Etude des Leucémies et Autres Maladies du Sang (GOELAMS) reports of their individual 
monosomal karyotype experiences also failed to reveal a single case of monosomy 5 occurring outside of MK+ 
AML.8,10,20  While these reports do not directly describe the frequency of monosomy 5 within their CK+ AML 
population, it should be noted that 89% (417/470) of the collective MK+ patients described by HOVON/SAKK, 
SWOG, GOELAMS carried the CK+ designation with CK+ defined as ≥ 3 clonal abnormalities in each analysis.   
       Although our data confirm that the prognosis for AML patients with monosomy 7 (in the absence of 
monosomal karyotype) is poor (Table 4), it should be noted that the negative prognostic impact of monosomy 7 
was lost in the context of MK+ AML (Figures 2C, 2D; Supplemental Table 2).  Although no difference in 
survival was seen by univariate analysis amongst MK+ / CK≥5+ / Monosomy 7+ patients compared to those 
without monosomy 7 (Figure 1D), the presence of monosomy 7 was actually observed to confer a statistically 
significant improvement in survival for MK+ patients regardless of karyotype complexity ≤4 or ≥5; 
Supplemental Table 2).   
While the poor prognostic impact of 17p aberrations21,22 and the collective group of chromosome 17 
abnormalities23,24 in AML have been demonstrated, the significance of monosomy 17 itself has not been well 
described.  In our experience monosomy 17 occurred exclusively (72/72) within the setting of MK+ disease and 
predominantly within the CK≥5+ population (68/72).  The presence of monosomy 17 identified a distinct 
subgroup of MK+ patients with an inferior OS (Figure 2F and Supplemental Figure 2).   
The strong association between monosomies and their occurrence in complex karyotypes illustrates the 
significant shortcomings of the current ISCN nomenclature when defining a “monosomy”.  Nearly all complex 
karyotypes with apparent monosomies have multiple concurrent unclassifiable portions of chromosomal 
material, i.e., “add” chromosomes, marker chromosomes or ring chromosomes, which likely represent portions 
of the missing monosomies listed in the ISCN.  In should also be noted that, the identification of double 
monosomies (loss of both copies of the same chromosome) is always accompanied by structural 
abnormalities, presumably representing critical portions of one of the missing chromosomes since true double 
monosomy is not compatible with cell viability.  Thus, evaluating the whole genome of leukemia cells via the 
emerging technologies of whole genome microarrays and next generation sequencing techniques25 will provide 
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more accurate characterization as to the extent of true chromosomal gains and losses associated with complex 
karyotypes with apparent monosomies.   
 Although numerous reports have demonstrated the association of dismal outcomes with AML patients 
of advanced age and the increased incidence of high-risk cytogenetic abnormalities among this population26-28, 
it should not be assumed that the prognostic impact of MK is simply a reflection of the advanced age of the 
population in which is more commonly occurs.  The data reported by HOVON/SAKK, SWOG, and GOELAMS 
has consistently demonstrated inferior outcomes among MK+ AML patients compared to their age-matched 
MK- counterparts.8,10,20  While the ECOG-ACRIN experience reported here also demonstrated an increased 
incidence of MK+ among older patients (≥55y) compared to their younger counterparts, the prognostic 
significance of MK+ occurring within less complex karyotypes (≤4 clonal abnormalities) was retained when 
controlling for age via multivariate analysis (Table 6).  It should also be noted that the prognostic significance of 
monosomy 17 (occurring exclusively within the MK+ population) was also retained when controlling for age by 
multivariate analysis regardless of karyotype complexity (Supplemental Table 3).  Our data further support the 
delineation of the risk group characterized by the presence of MK+ with subgroups possessing similar median 
OS regardless of karyotype complexity (Supplemental Figure 1).  Median OS of CK+/MK- disease was twice 
that of CK+/MK+ patients and was best among those with CK-/MK- AML.  
 The ECOG-ACRIN experience demonstrates that CK≥5 and MK+ (with karyotype complexity ≤4) 
designations reliably predict poor outcomes for which no consistently effective therapeutic strategy has yet 
been identified.  Allogeneic HSCT and possibly the incorporation of high-dose cytarabine29 into a patient’s 
therapeutic regimen may improve outcomes.  However, the benefit of these treatments appears marginal and 
advanced age and resultant comorbidities limit the feasibility of these therapies for many CK≥5 and MK+ 
patients.  While allogeneic HSCT appears to be the only potentially curative option available, overall outcomes 
remain poor with HSCT of MK+ patients yielding a 4-year OS of 25% compared to 0% without transplant as 
reported by the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.30  Similarly, the 
Center for International Blood and Marrow Transplant Research has reported a 3-year OS of 29% and that 
MK+ AML patients was associated with higher mortality (p<0.001; RR 1.67; 95%CI 1.38, 2.01) than that of 
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normal karyotype AML patients undergoing HSCT.31  Cumulative relapse incidences of MK+ patients at 3-
years have been reported at 52-62% for those transplanted in CR131,32 and 67% for those transplanted beyond 
CR1.32   
 Although AML is often treated uniformly, it is increasingly evident that this disease is largely 
heterogeneous with genetically distinct subgroups.  The possibility exists that prior lack of awareness of 
disease subgroups, such as MK+ disease, has negatively impacted outcomes and inhibited the advancement 
of therapeutic options for better risk subgroups.  Inclusion of the MK+ patient population and its dismal 
prognosis on clinical trials along with relatively better risk AML patients may obscure the recognition of 
therapeutic benefits for patients with better risk disease.  Accounting for these subgroups via mechanisms 
such as the hierarchical classification according to specific chromosomal lesions as proposed by Middeke et 
al22 may enable more appropriate selection of patients for particular therapeutic modalities such as allogeneic 
HSCT.  They describe the ability to select MK+ patients with better HSCT outcomes based on the presence or 
absence of abnl(17p) or monosomy 5 / del(5q) lesions.  Given the association of TP53 abnormalities with MK+ 
AML33, the authors allude to the possibility that TP53 abnormalities may play a role in resistance of this MK+ 
subset against the graft-versus-leukemia effect of allogeneic HSCT.22  Of note, TP53 mutation status was 
known on six of the monosomy 17 patients included in our analysis and, interestingly, none of these six were 
found to possess TP53 mutations.  As such, the true degree to which TP53 abnormalities or possible 
aberrations associated with the loss of genes on 17q such as ERBB2, NF1, RARA, BRCA1, or STAT3 
contribute to resistance within monosomy 17 patients is unknown and warrants further investigation.         
 With the potential promise of molecular targeting it is imperative that we decipher the pathophysiologic 
mechanisms associated with the poor outcome of MK+ AML patients. Thoughtful design of future AML clinical 
trials, accurate identification of a patient’s cytogenetic/molecular risk profile prior to trial enrollment, and 
investigation of more homogenous AML subgroups may open the door to therapeutic advances and improved 
outcomes that have been lacking in this disease.  The feasibility of such an approach is currently under 
investigation [NCT01684150] based on the discovery that DOT1L inhibition is able to induce selective 
cytotoxicity in poor risk MLL-rearranged leukemic cells while sparing non-rearranged cells.34,35   Similarly, the 
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prevalence of TP53 alterations within CK+ AML33 makes p53 a potentially attractive target to explore in this 
population.  Although targeting p53 has presented significant challenges in the past, agents are now available 
which restore wild-type activity to mutant p53  proteins (APR-24636,37) and agents which disrupt MDM/p53 
interactions (RG7112 38,39,  JNJ-26854165 40) and subsequently lead to apoptosis.41  
 In conclusion, while MK is an independent predictor of outcomes in adult AML patients, our data 
suggest the prognostic utility of the MK+ designation appeared to be limited to those with less complex 
karyotypes (complexity ≤4).  Our study draws into question the independent prognostic value of monosomy 5 
as this monosomy occurred almost exclusively in MK+ and CK≥5 patients.  The majority of monosomy 7 
occurrences appeared in the context of MK+ disease where its prognostic value was lost regardless of 
karyotype complexity.  Although the independent significance of monosomy 5 and monosomy 7 were lacking 
within the context of MK+ AML, monosomy 17 defined a distinct subcategory of MK+ AML.  The very poor 
prognosis associated with MK+/CK≤4 AML, monosomy 17+ AML, and highly complex (CK≥5) AML 
underscores the need for better understanding of the genetic aberrations and potential targets present within 
these karyotypes to guide investigation of novel therapeutic strategies in this group of patients. 
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Figure Legend: 
Figure 1. Overall Survival according to Monosomal Karyotype status and Karyotype Complexity among 
patients with Non-CBF clonal cytogenetic abnormalities 
A. Overall Survival of patients with or without MK and karyotype complexity ≤ 4  
B. Overall Survival of patients with or without MK and karyotype complexity ≥ 5  
  
Figure 2. Overall Survival of MK patients according to Monosomy 5, Monosomy 7, or Monosomy 17 
status and Karyotype Complexity 
A. Overall Survival of MK+ patients with karyotype complexity ≤ 4 with or without Monosomy 5 
B. Overall Survival of MK+ patients with karyotype complexity ≥ 5 with or without Monosomy 5 
C. Overall Survival of MK+ patients with karyotype complexity ≤ 4 with or without Monosomy 7 
D. Overall Survival of MK+ patients with karyotype complexity ≥ 5 with or without Monosomy 7 
E. Overall Survival of MK+ patients with karyotype complexity ≤ 4 with or without Monosomy 17 
F. Overall Survival of MK+ patients with karyotype complexity ≥ 5 with or without Monosomy 17 
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Figure 1. Overall Survival according to Monosomal Karyotype status and Karyotype Complexity among 
Patients with Non-CBF Clonal Cytogenetic Abnormalities 
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HR: 1.98 (1.40, 2.81) 
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HR: 1.06 (0.66, 1.68) 
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Figure 2. Overall Survival of MK patients according to Monosomy 5, Monosomy 7, or 
Monosomy 17 status and Karyotype Complexity 
A.  
 
HR: 4.13 (0.82, 20.8) 
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HR: 0.99 (0.69, 1.41) 
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HR: 0.76 (0.37, 1.53) 
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HR: 0.86 (0.61, 1.21) 
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HR: 3.11 (0.90, 10.7) 
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Table Legend: 
Table 1. Cytogenetic categorization of 1188 Acute Myeloid Leukemia Patients on ECOG-ACRIN Therapeutic 
Trials (E1490, E1900,E3993,E3999) 
Table 2. Baseline Characteristics by Monosomal Karyotype Status 
Table 3. Distribution of Chromosomal Monosomies and Associated Outcomes   
Table 4. Outcome Measures by Monosomal Karyotype Status Among Patients with Non-CBF Clonal 
Cytogenetic Abnormalities 
 
Table 5. Outcome Measures by Karyotype Complexity and Monosomal Karyotype Status Among Patients with 
Non-CBF Clonal Cytogenetic Abnormalities 
 
Table 6. Multivariate Analysis of Monosomal Karyotype, Karyotype Complexity, and Independent High-Risk 
Cytogenetic Abnormalities Among Patients with Non-CBF Clonal Cytogenetic Abnormalities 
 
HR: 1.53 (1.09, 2.13) 
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Table 1. Cytogenetic categorization of 1188 Acute Myeloid Leukemia 
Patients on ECOG-ACRIN Therapeutic Trials (E1490,E1900,E3993,E3999) 
Karyotype N % 
Normal 502 42 
Clonal Abnormalities 686 58 
- CBF 108 9 
- Single Monosomy 97 8 
- Multiple Monosomies 132 11 
- Complex  251 21 
- Monosomal 195 16 
 
 
 
 
 
 
 
Table 2. Baseline Characteristics by Monosomal Karyotype Status 
 
MK- MK+ Total P-
value Median Min Max Median Min Max Median Min Max 
AGE 
59.0 17 93 65.0 20 86 61.0 17 93 <0.001 
Peripheral WBC count 
(/mm3)(x1000) 
10.0 1 213 3.5 0 200 8.6 0 213 <0.001 
Hemoglobin 9.2 4 30 8.9 5 13 9.1 4 30 0.009 
Peripheral Blasts (%) 
26.0 0 98 9.0 0 98 23.0 0 98 <0.001 
Peripheral platelet count 
(/mm3)(x1000) 
55.0 1 650 43.0 5 995 53.0 1 995 0.002 
Marrow Blasts (%) 
62.0 1 100 48.5 0 100 60.0 0 100 <0.001 
 N % N % N %  
Secondary AML 
126 12.7 45 23.1 171 14.4 <0.001 
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Table 3. Distribution of Chromosomal Monosomies and Associated Outcomes 
 
Single Monosomy ≥ 2 Monosomies 
N 
N of 
CR CR% 
4-Year 
OS %* SE N 
N of 
CR CR% 
4-Year 
OS %* SE 
All patients** 97 25 25.8 7 3 132 47 35.6 2 1 
Non-CBF 96 25 26.0 6 2 132 47 35.6 2 1 
Mono 1 1 1 100.0 . . 7 2 28.6 . . 
Mono 2 . . . . . 7 4 57.1 . . 
Mono 3 1 1 100.0 . . 24 13 54.2 0 . 
Mono 4 . . . . . 14 7 50.0 7 7 
Mono 5 2 1 50.0 . . 52 18 34.6 2 2 
Mono 6 1 0 0 . . 14 7 50.0 0 . 
Mono 7 51 15 29.4 10 4 56 20 35.7 4 2 
Mono 8 2 0 0 . . 6 2 33.3 . . 
Mono 9 . . . . . 15 5 33.3 7 6 
Mono 10 1 1 100.0 . . 15 7 46.7 0 . 
Mono 11 2 1 50.0 . . 12 5 41.7 0 . 
Mono 12 2 1 50.0 . . 24 9 37.5 8 6 
Mono 13 5 2 40.0 . . 20 11 55.0 5 5 
Mono 14 4 1 25.0 . . 12 7 41.7 0 . 
Mono 15 1 0 0 . . 6 0 0 . . 
Mono 16 3 1 33.3 . . 22 6 27.3 0 . 
Mono 17 8 0 0 . . 64 25 39.1 0 . 
Mono 18 2 0 0 . . 40 18 45.0 2 2 
Mono 19 4 1 25.0 . . 9 5 55.6 . . 
Mono 20 4 1 25.0 . . 28 7 25.0 0 . 
Mono 21 3 . . . . 30 12 40.0 3 3 
Mono 22 . . . . . 14 5 35.7 0 . 
   *OS was estimated only for subgroups with ≥ 10 patients  
   **One patient demonstrated a single monosomy in association with a CBF abnormality 
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Table 4. Outcome Measures by Monosomal Karyotype Status  
Among Patients with Non-CBF Clonal Cytogenetic Abnormalities  
 
MK- MK+ 
P-value** 
N N of CR CR% 4-Year OS % SE N N of CR CR% 4-Year OS % SE# 
Age (yrs)            
Age < 55 107 63 58.9 27 4 25 10 40.0 16 7 0.02 
Age ≥ 55 276 116 42.0 10 2 170 51 30.0 1 1 <0.001 
CK*            
No 314 153 48.7 15 2 13 2 15.4 8 7 0.04 
Yes 69 26 37.7 12 4 182 59 32.4 3 1 <0.001 
Neither Monosomy 5,  
nor Monosomy 7,  
nor Monsomy 17 
354 169 47.7 14 2 52 14 26.9 4 3 <0.001 
Monosomy 5, 
w/o Monosomy 7, 
w/o Monosomy 17 
1 1 100.0 0 . 12 3 25.0 0 . 0.14 
Monosomy 7, 
w/o Monosomy 5,  
w/o monosomy 17 
28 9 32.1 11 6 46 14 30.4 7 4 0.10 
Monosomy 5,  
Monosomy 7, 
w/o monosomy 17 
0 0 . . . 13 5 38.5 8 7 . 
Monosomy 17, 
w/o Monosomy 5, 
w/o Monosomy 7 
0 0 . . . 33 12 36.4 0 . . 
Monosomy 5, 
Monosomy 17, 
w/o Monosomy 7 
0 0 . . . 19 6 31.6 0 . . 
Monosomy 7, 
Monosomy 17, 
w/o Monosomy 5 
0 0 . . . 11 3 27.3 0 . . 
Monosomy 5, 
Monosomy 7, 
Monosomy 17 
0 0 . . . 9 4 44.4 0 . . 
Total 383 179 46.7 14 2 195 61 31.3 3 1 <0.001 
* CK: defined as patients with ≥ 3 clonal abnormalities              
** p-values are based on log-rank test of OS                                 
# SE represents standard error  
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Table 5. Outcome Measures by Karyotype Complexity and Monosomal Karyotype Status 
Among Patients with Non-CBF Clonal Cytogenetic Abnormalities 
 
MK- MK+ 
P-value** 
N N of CR CR% 4-Year OS % SE† N N of CR CR% 4-Year OS % SE† 
# of abnormalities            
≤ 4 359 170 47.4 14 2 37 8 21.6 5 4 <0.001 
≥ 5 24 9 37.5 13 7 158 53 33.5 3 1 0.82 
** p-values are based on log-rank test of OS 
† SE represents standard error 
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Table 6. Multivariate Analysis of Monosomal Karyotype, Karyotype Complexity, and Independent High-Risk Cytogenetic Abnormalities 
Among Patients with Non-CBF Clonal Cytogenetic Abnormalities 
 Karyotype Complexity ≤ 4 Clonal Abnormalities  Karyotype Complexity ≥ 5 Clonal Abnormalities  
Parameter P-value 
Hazard 
Ratio 
95% Hazard Ratio 
Confidence Limits 
P-value 
Hazard 
Ratio 
95% Hazard Ratio 
Confidence Limits 
MK Yes vs no 0.01 1.78 1.13 2.79 0.47 1.22 0.72 2.06 
# of abnormality 3 vs. <3 0.77 1.06 0.71 1.58 - - - - 
# of abnormality 4 vs. <3 0.08 1.55 0.95 2.54 - - - - 
Gender (Male vs. female) 0.63 1.06 0.83 1.36 0.79 1.05 0.73 1.52 
Age (yrs) (Age >=55 vs. <55) 0.08 1.47 0.95 2.25 0.05 1.99 1.01 3.91 
WBC (cells/mm3) >=10,000 vs. <10,000 0.001 1.57 1.20 2.06 0.79 1.07 0.66 1.73 
Hemoglobin (g/dL) hg>=10 vs. <10 0.92 1.02 0.77 1.33 0.97 0.99 0.65 1.51 
Platelets (cells/mm3) >=10,000 vs. <10,000 0.19 0.64 0.33 1.24 0.30 0.66 0.30 1.45 
Marrow: %BLAST 0.52 1.00 0.99 1.00 0.90 1.00 0.99 1.01 
BLOOD:%BLASTS, 0.06 1.00 1.00 1.01 0.002 1.01 1.01 1.02 
Secondary AML (Yes vs. no) 0.003 1.58 1.17 2.15 0.98 1.01 0.63 1.60 
del(5q) 0.16 1.38 0.88 2.16 0.87 0.97 0.68 1.40 
del(7q) 0.10 0.53 0.24 1.14 0.25 0.75 0.46 1.23 
del(17p) 0.12 2.28 0.81 6.38 0.94 1.03 0.42 2.52 
inv(3) 0.01 2.08 1.19 3.65 0.97 1.05 0.12 9.36 
t(6;9) 0.61 1.36 0.42 4.43 . . . . 
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Table 6. Multivariate Analysis of Monosomal Karyotype, Karyotype Complexity, and Independent High-Risk Cytogenetic Abnormalities 
Among Patients with Non-CBF Clonal Cytogenetic Abnormalities 
 Karyotype Complexity ≤ 4 Clonal Abnormalities  Karyotype Complexity ≥ 5 Clonal Abnormalities  
Parameter P-value 
Hazard 
Ratio 
95% Hazard Ratio 
Confidence Limits 
P-value 
Hazard 
Ratio 
95% Hazard Ratio 
Confidence Limits 
11q23 0.09 1.60 0.92 2.77 0.49 1.52 0.47 4.88 
t(9;22) 0.07 2.33 0.92 5.88 . . . . 
 
 
